Erratum: Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein (Journal of Virology (2014) 88:2 (1259-1270) DOI: 10.1128/JVI.03148-13);Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein

Journal of Virology

Volumn 88, Issue 2, 2014, Pages 1259-1270

  Yin, Xin ^a,b   Hu, Zhe ^a   Gu, Qinyong ^a,b   Wu, Xingliang ^a   Zheng, Yong Hui ^c   Wei, Ping ^b   Wang, Xiaojun ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^c Michigan State University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; TETHERIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHROMOSOME 21; CONSENSUS SEQUENCE; EQUINE INFECTIOUS ANEMIA VIRUS; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RETROVIRUS; VIRION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS RELEASE; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD; BASE SEQUENCE; CATS; CELL LINE; CLONING, MOLECULAR; EQUINE INFECTIOUS ANEMIA; HORSES; HUMANS; INFECTIOUS ANEMIA VIRUS, EQUINE; MICE; MOLECULAR SEQUENCE DATA; RETROVIRIDAE; SEQUENCE ALIGNMENT; VIRAL ENVELOPE PROTEINS; VIRUS RELEASE;

EID: 84891705762     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02163-20     Document Type: Erratum

References (57)

1. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430. http://dx.doi.org/10.1038/nature06553.
2. Pardieu C, Vigan R, Wilson SJ, Calvi A, Zang T, Bieniasz P, Kellam P, Towers GJ, Neil SJ. 2010. The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog. 6:e1000843. http://dx.doi.org/10.1371/journal.ppat.1000843.
3. Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y, McNatt M, Hatziioannou T, Bieniasz PD. 2009. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 83:1837-1844. http://dx.doi.org/10.1128/JVI.02211-08.
4. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. 2009. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 106:2886-2891. http://dx.doi.org/10.1073/pnas.0811014106.
5. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J. 2009. Inhibition of Lassa and Marburg virus production by tetherin. J. Virol. 83:2382-2385. http://dx.doi.org/10.1128/JVI.01607-08.
6. Mansouri M, Viswanathan K, Douglas JL, Hines J, Gustin J, Moses AV, Fruh K. 2009. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J. Virol. 83:9672-9681. http://dx.doi.org/10.1128/JVI.00597-09.
7. Radoshitzky SR, Dong L, Chi X, Clester JC, Retterer C, Spurgers K, Kuhn JH, Sandwick S, Ruthel G, Kota K, Boltz D, Warren T, Kranzusch PJ, Whelan SP, Bavari S. 2010. Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J. Virol. 84:10569-10580. http://dx.doi.org/10.1128/JVI.00103-10.
8. Jones PH, Mehta HV, Maric M, Roller RJ, Okeoma CM. 2012. Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo. Retrovirology 9:10. http://dx.doi.org/10.1186/1742-4690-9-10.
9. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT. 2010. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J. Virol. 84:12646-12657. http://dx.doi.org/10.1128/JVI.01328-10.
10. Mattiuzzo G, Ivol S, Takeuchi Y. 2010. Regulation of porcine endogenous retrovirus release by porcine and human tetherins. J. Virol. 84:2618-2622. http://dx.doi.org/10.1128/JVI.01928-09.
11. Arnaud F, Black SG, Murphy L, Griffiths DJ, Neil SJ, Spencer TE, Palmarini M. 2010. Interplay between ovine bone marrow stromal cell antigen 2/tetherin and endogenous retroviruses. J. Virol. 84:4415-4425. http://dx.doi.org/10.1128/JVI.00029-10.
12. Liberatore RA, Bieniasz PD. 2011. Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 108:18097-18101. http://dx.doi.org/10.1073/pnas.1113694108.
13. Goffinet C, Schmidt S, Kern C, Oberbremer L, Keppler OT. 2010. Endogenous CD317/Tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses. J. Virol. 84:11374-11384. http://dx.doi.org/10.1128/JVI.01067-10.
14. Fukuma A, Abe M, Morikawa Y, Miyazawa T, Yasuda J. 2011. Cloning and characterization of the antiviral activity of feline Tetherin/BST-2. PLoS One 6:e18247. http://dx.doi.org/10.1371/journal.pone.0018247.
15. Dietrich I, McMonagle EL, Petit SJ, Vijayakrishnan S, Logan N, Chan CN, Towers GJ, Hosie MJ, Willett BJ. 2011. Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection. J. Virol. 85:5840-5852. http://dx.doi.org/10.1128/JVI.00071-11.
16. Celestino M, Calistri A, Del Vecchio C, Salata C, Chiuppesi F, Pistello M, Borsetti A, Palu G, Parolin C. 2012. Feline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein. J. Virol. 86:6688-6700. http://dx.doi.org/10.1128/JVI.07037-11.
17. Barrett BS, Smith DS, Li SX, Guo K, Hasenkrug KJ, Santiago ML. 2012. A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo. PLoS Pathog. 8:e1002596. http://dx.doi.org/10.1371/journal.ppat.1002596.
18. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. 2003. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4:694-709. http://dx.doi.org/10.1034/j.1600-0854.2003.00129.x.
19. Moore RC, Lee IY, Silverman GL, Harrison PM, Strome R, Heinrich C, Karunaratne A, Pasternak SH, Chishti MA, Liang Y, Mastrangelo P, Wang K, Smit AF, Katamine S, Carlson GA, Cohen FE, Prusiner SB, Melton DW, Tremblay P, Hood LE, Westaway D. 1999. Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. J. Mol. Biol. 292:797-817. http://dx.doi.org/10.1006/jmbi.1999.3108.
20. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, Bieniasz PD. 2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499-511. http://dx.doi.org/10.1016/j.cell.2009.08.039.
21. Ishikawa J, Kaisho T, Tomizawa H, Lee BO, Kobune Y, Inazawa J, Oritani K, Itoh M, Ochi T, Ishihara K, Hirano T. 1995. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 26:527-534. http://dx.doi.org/10.1016/0888-7543(95)80171-H.
22. Vidal-Laliena M, Romero X, March S, Requena V, Petriz J, Engel P. 2005. Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry. Cell. Immunol. 236:6-16. http://dx.doi.org/10.1016/j.cellimm.2005.08.002.
23. Blasius AL, Giurisato E, Cella M, Schreiber RD, Shaw AS, Colonna M. 2006. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J. Immunol. 177:3260-3265. http://www.jimmunol.org/content/177/5/3260.
24. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. 2009. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 5:e1000574. http://dx.doi.org/10.1371/journal.ppat.1000574.
25. Miyagi E, Andrew AJ, Kao S, Strebel K. 2009. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc. Natl. Acad. Sci. U. S. A. 106:2868-2873. http://dx.doi.org/10.1073/pnas.0813223106.
26. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252. http://dx.doi.org/10.1016/j.chom.2008.03.001.
27. Rong L, Zhang J, Lu J, Pan Q, Lorgeoux RP, Aloysius C, Guo F, Liu SL, Wainberg MA, Liang C. 2009. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J. Virol. 83:7536-7546. http://dx.doi.org/10.1128/JVI.00620-09.
28. Erikson E, Adam T, Schmidt S, Lehmann-Koch J, Over B, Goffinet C, Harter C, Bekeredjian-Ding I, Sertel S, Lasitschka F, Keppler OT. 2011. In vivo expression profile of the antiviral restriction factor and tumortargeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc. Natl. Acad. Sci. U. S. A. 108:13688-13693. http://dx.doi.org/10.1073/pnas.1101684108.
29. Le Tortorec A, Neil SJ. 2009. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 83:11966-11978. http://dx.doi.org/10.1128/JVI.01515-09.
30. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM. 2010. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 7:51. http://dx.doi.org/10.1186/1742-4690-7-51.
31. Gupta RK, Mlcochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, Pillay D, Takeuchi Y, Marsh M, Towers GJ. 2009. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc. Natl. Acad. Sci. U. S. A. 106:20889-20894. http://dx.doi.org/10.1073/pnas.0907075106.
32. Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J, Cannon PM. 2010. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J. Virol. 84:7243-7255. http://dx.doi.org/10.1128/JVI.02636-09.
33. Leroux C, Cadore JL, Montelaro RC. 2004. Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us? Vet. Res. 35:485-512. http://dx.doi.org/10.1051/vetres:2004020.
34. Leroux C, Craigo JK, Issel CJ, Montelaro RC. 2001. Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies. J. Virol. 75:4570-4583. http://dx.doi.org/10.1128/JVI.75.10.4570-4583.2001.
35. Hammonds J, Wang JJ, Yi H, Spearman P. 2010. Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog. 6:e1000749. http://dx.doi.org/10.1371/journal.ppat.1000749.
36. Zheng YH, Jeang KT, Tokunaga K. 2012. Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology 9:112. http://dx.doi.org/10.1186/1742-4690-9-112.
37. Malim MH, Bieniasz PD. 2012. HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med. 2:a006940. http://dx.doi.org/10.1101/cshperspect.a006940.
38. Mitrophanous K, Yoon S, Rohll J, Patil D, Wilkes F, Kim V, Kingsman S, Kingsman A, Mazarakis N. 1999. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 6:1808-1818. http://dx.doi.org/10.1038/sj.gt.3301023.
39. Balaggan KS, Binley K, Esapa M, Iqball S, Askham Z, Kan O, Tschernutter M, Bainbridge JW, Naylor S, Ali RR. 2006. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors. J. Gene Med. 8:275-285. http://dx.doi.org/10.1002/jgm.845.
40. Zielonka J, Bravo IG, Marino D, Conrad E, Perkovic M, Battenberg M, Cichutek K, Munk C. 2009. Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases. J. Virol. 83:7547-7559. http://dx.doi.org/10.1128/JVI.00015-09.
41. Bogerd HP, Tallmadge RL, Oaks JL, Carpenter S, Cullen BR. 2008. Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism. J. Virol. 82:11889-11901. http://dx.doi.org/10.1128/JVI.01537-08.
42. Evans DT, Serra-Moreno R, Singh RK, Guatelli JC. 2010. BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol. 18:388-396. http://dx.doi.org/10.1016/j.tim.2010.06.010.
43. Masuyama N, Kuronita T, Tanaka R, Muto T, Hirota Y, Takigawa A, Fujita H, Aso Y, Amano J, Tanaka Y. 2009. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J. Biol. Chem. 284:15927-15941. http://dx.doi.org/10.1074/jbc.M109.005124.
44. Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G. 2007. Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J. Cell Sci. 120:3850-3858. http://dx.doi.org/10.1242/jcs.003343.
45. Boucrot E, Saffarian S, Zhang R, Kirchhausen T. 2010. Roles of AP-2 in clathrin-mediated endocytosis. PLoS One 5:e10597. http://dx.doi.org/10.1371/journal.pone.0010597.
46. Dube M, Roy BB, Guiot-Guillain P, Binette J, Mercier J, Chiasson A, Cohen EA. 2010. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 6:e1000856. http://dx.doi.org/10.1371/journal.ppat.1000856.
47. Habermann A, Krijnse-Locker J, Oberwinkler H, Eckhardt M, Homann S, Andrew A, Strebel K, Krausslich HG. 2010. CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. J. Virol. 84:4646-4658. http://dx.doi.org/10.1128/JVI.02421-09.
48. Andrew AJ, Miyagi E, Kao S, Strebel K. 2009. The formation of cysteinelinked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 6:80. http://dx.doi.org/10.1186/1742-4690-6-80.
49. Neil SJ, Sandrin V, Sundquist WI, Bieniasz PD. 2007. An interferonalpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2:193-203. http://dx.doi.org/10.1016/j.chom.2007.08.001.
50. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, Evans DT. 2009. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 5:e1000429. http://dx.doi.org/10.1371/journal.ppat.1000429.
51. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, Johnson WE, Neil SJ, Bieniasz PD. 2009. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 5:e1000300. http://dx.doi.org/10.1371/journal.ppat.1000300.
52. Goffinet C, Allespach I, Homann S, Tervo HM, Habermann A, Rupp D, Oberbremer L, Kern C, Tibroni N, Welsch S, Krijnse-Locker J, Banting G, Krausslich HG, Fackler OT, Keppler OT. 2009. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5:285-297. http://dx.doi.org/10.1016/j.chom.2009.01.009.
53. Tokarev AA, Munguia J, Guatelli JC. 2011. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J. Virol. 85:51-63. http://dx.doi.org/10.1128/JVI.01795-10.
54. Fagerness AJ, Flaherty MT, Perry ST, Jia B, Payne SL, Fuller FJ. 2006. The S2 accessory gene of equine infectious anemia virus is essential for expression of disease in ponies. Virology 349:22-30. http://dx.doi.org/10.1016/j.virol.2005.12.041.
55. Li F, Leroux C, Craigo JK, Cook SJ, Issel CJ, Montelaro RC. 2000. The S2 gene of equine infectious anemia virus is a highly conserved determinant of viral replication and virulence properties in experimentally infected ponies. J. Virol. 74:573-579. http://dx.doi.org/10.1128/JVI.74.1.573-579.2000.
56. Li F, Puffer BA, Montelaro RC. 1998. The S2 gene of equine infectious anemia virus is dispensable for viral replication in vitro. J. Virol. 72:8344-8348.
57. Kuhl A, Banning C, Marzi A, Votteler J, Steffen I, Bertram S, Glowacka I, Konrad A, Sturzl M, Guo JT, Schubert U, Feldmann H, Behrens G, Schindler M, Pohlmann S. 2011. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J. Infect. Dis. 204(Suppl 3):S850-S860. http://dx.doi.org/10.1093/infdis/jir378.